Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | HTR2C | P28335 | 2/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL8146164 | 0.89 | HTR1A (0.47) | HTR2AHTR2CHTR2BHTR1AKDM4E | |
| Fumaric Acid SCHEMBL8146172 | 0.89 | HTR1A (0.47) | HTR2AHTR2CHTR2BHTR1AKDM4E | |
| SCHEMBL17253616 | 0.88 | KDM4E (0.46) | HTR2AHTR2CHTR2BHTR1AKDM4E | |
| SCHEMBL6221858 | 0.86 | PRKAG1 (0.45) | HTR2AHTR2CHTR2BHTR1AKDM4E | |
| SCHEMBL6221861 | 0.86 | PRKAG1 (0.45) | HTR2AHTR2CHTR2BHTR1AKDM4E | |
| SCHEMBL19068712 | 0.84 | HTR2A (0.43) | HTR2AHTR2CHTR2BHTR1AKDM4E | |
| SCHEMBL17221269 | 0.82 | HTR2B (0.53) | HTR2AHTR2CHTR2BHTR1AKDM4E | |
| SCHEMBL5990709 | 0.82 | HTR1B (0.46) | HTR2AHTR2CHTR2BHTR1ATTK | |
| SCHEMBL17232485 | 0.80 | KDM4E (0.50) | HTR2AHTR2CHTR2BHTR1AKDM4E | |
| SCHEMBL14734878 | 0.80 | KDM4E (0.50) | HTR2AHTR2CHTR2BKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7005443-B1 | 5-Hydroxy indazole derivatives for treating glaucoma | ALCON, INC. (CH) | 2006-02-28 | — | — | US | claimed |
| EP-1268439-A1 | 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | Alcon Inc. (CH) | 2003-01-02 | — | — | EP | claimed |
| WO-2001070701-A1 | 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | claimed |
| WO-2000012482-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-20110152272-A1 | Treatment Of Incontinence | PFIZER INC | 2011-06-23 | — | — | US | disclosed |
| EP-2277513-A2 | Treatment of incontinence with 5htc2 agonists | Pfizer Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20080146583-A1 | Treatment of Incontinence | PFIZER INC | 2008-06-19 | — | — | US | disclosed |
| US-20060052431-A1 | 5-Hydroxy indazole derivatives for treating glaucoma | MAY JESSE A | 2006-03-09 | — | — | US | disclosed |
| US-7005443-B1 | 5-Hydroxy indazole derivatives for treating glaucoma | ALCON, INC. (CH) | 2006-02-28 | — | — | US | disclosed |
| EP-1620081-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | Pfizer Limited (GB) | 2006-02-01 | — | — | EP | disclosed |
| US-20040235856-A1 | Treatment of incontinence | PFIZER INC | 2004-11-25 | — | — | US | disclosed |
| WO-2004096196-A2 | TREATMENT OF INCONTINENCE WITH 5HTC2 AGONISTS | PFIZER LIMITED (GB) | 2004-11-11 | — | — | WO | disclosed |
| EP-1268439-A1 | 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | Alcon Inc. (CH) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001070701-A1 | 5-HYDROXY INDAZOLE DERIVATIVES FOR TREATING GLAUCOMA | ALCON, INC. (CH) | 2001-09-27 | — | — | WO | disclosed |
| WO-2000012482-A2 | INDAZOLE DERIVATIVES WITH 5-HT2 RECEPTOR ACTIVITY | VERNALIS RESEARCH LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052431-A1 | 5-Hydroxy indazole derivatives for treating glaucoma | PTGIS, PTGIR, PDE3A | HTR2A 1456/4885HTR2C 929/4885HTR2B 1428/4885 |
| US-20040235856-A1 | Treatment of incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20110152272-A1 | Treatment Of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
| US-20080146583-A1 | Treatment of Incontinence | HTR2C, HTR5A, ADRA2C | HTR2A 6/4885HTR2C 1/4885HTR2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.